Transcriptomic and Epigenomic Profiling of Histone Deacetylase Inhibitor Treatment Reveals Distinct Gene Regulation Profiles Leading to Impaired Neutrophil Development

The clinical use of histone deacetylase inhibitors (HDACi) for the treatment of bone marrow failure and hematopoietic malignancies has increased dramatically over the last decades. Nonetheless, their effects on normal myelopoiesis remain poorly evaluated. Here, we treated cord blood derived CD34+ pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Govers, Anita M.A.P., Wiggers, Caroline R.M., van Boxtel, Ruben, Mokry, Michal, Nieuwenhuis, Edward E.S., Creyghton, Menno P., Bartels, Marije, Coffer, Paul J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745919/
https://www.ncbi.nlm.nih.gov/pubmed/31723844
http://dx.doi.org/10.1097/HS9.0000000000000270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745919/
https://www.ncbi.nlm.nih.gov/pubmed/31723844
http://dx.doi.org/10.1097/HS9.0000000000000270

Ejemplares similares